Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 1/2016

17.12.2015 | Original Article

High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??

verfasst von: Saptarshi Ghosh, Pamidimukalabramhananda Rao

Erschienen in: The Journal of Obstetrics and Gynecology of India | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Though high dose rate (HDR) intracavitary brachytherapy (ICBT) is now an integral part in the treatment of cervical cancer, the quest for optimum dose and fractionation schedule is still ongoing. While the American Brachytherapy Society recommends individual fraction size of <7.5 Gy, there are few studies where the authors obtained similar results with higher dose per fraction.

Objective

To compare and analyse two high-dose-rate intracavitary brachytherapy schedules—7 Gy per fraction for three fractions with 9 Gy per fraction for two fractions.

Materials and Methods

This is a prospective institutional study in Southern India carried on from 1 June 2012 to 31 March 2013. In this period, 124 patients of cervical cancer satisfying our inclusion criteria were treated with concurrent chemo-radiation, following which patients were randomized to one of the treatment arms, with 62 patients in each arm. The ICBT dose in Control Arm A was 7 Gy per fraction in three fractions, 1 week apart. While in Study Arm B, the ICBT dose was 9 Gy per fraction in two fractions, again 1 week apart. One patient in Arm A and three patients in Arm B discontinued the treatment even after repeated counselling and hence were excluded from the study analysis.

Results

The median follow-up period in the study was 25.2 months. In the Control Arm A, the 2-year actuarial local control rate, disease-free survival and overall survival were 88.5, 86.9 and 92.6 %, respectively, while in the Study Arm B, the 2-year actuarial local control rate, disease-free survival and overall survival were 91.5, 88.1 and 86.4 %, respectively.

Conclusion

In our experience, HDR brachytherapy with 9 Gy per fraction in two fractions is an effective dose fractionation when compared to 7 Gy per fraction in three fractions.
Literatur
3.
Zurück zum Zitat Sood BM, Gorla G, Gupta S, et al. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:702–6.CrossRefPubMed Sood BM, Gorla G, Gupta S, et al. Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys. 2002;53:702–6.CrossRefPubMed
4.
Zurück zum Zitat Nakano T, Kato S, Ohno T, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103:92–101.CrossRefPubMed Nakano T, Kato S, Ohno T, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005;103:92–101.CrossRefPubMed
5.
Zurück zum Zitat Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48(1):201–11.CrossRefPubMed Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48(1):201–11.CrossRefPubMed
6.
Zurück zum Zitat Patel FD, Kumar P, Karunanidhi G, et al. Optimization of high-dose-rate intracavitary brachytherapy schedule in the treatment of carcinoma of the cervix. Brachytherapy. 2011;02(10):147–53.CrossRef Patel FD, Kumar P, Karunanidhi G, et al. Optimization of high-dose-rate intracavitary brachytherapy schedule in the treatment of carcinoma of the cervix. Brachytherapy. 2011;02(10):147–53.CrossRef
7.
Zurück zum Zitat Patel FD, Rai B, Mallick I, et al. High-dose-rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:125–30.CrossRefPubMed Patel FD, Rai B, Mallick I, et al. High-dose-rate brachytherapy in uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:125–30.CrossRefPubMed
8.
Zurück zum Zitat Patel FD, Sharma SC, Negi PS, et al. Low dose rate versus high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys. 1994;28(2):335–41.CrossRefPubMed Patel FD, Sharma SC, Negi PS, et al. Low dose rate versus high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys. 1994;28(2):335–41.CrossRefPubMed
9.
Zurück zum Zitat ICRU Report #38. Dose and volume specification for reporting intracavitary therapy in oncology. International Commission on Radiation Units and Measurements. Bethesda. March 1985:1. ICRU Report #38. Dose and volume specification for reporting intracavitary therapy in oncology. International Commission on Radiation Units and Measurements. Bethesda. March 1985:1.
10.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
11.
Zurück zum Zitat Petereit DG, Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys. 1999;43:359–66.CrossRefPubMed Petereit DG, Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys. 1999;43:359–66.CrossRefPubMed
12.
Zurück zum Zitat Orton GC, Seyedsadr M, Somnay A. Comparison of high and low dose rate remote after loading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys. 1991;21:1425–34.CrossRefPubMed Orton GC, Seyedsadr M, Somnay A. Comparison of high and low dose rate remote after loading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys. 1991;21:1425–34.CrossRefPubMed
13.
Zurück zum Zitat Orton GC. Width of the therapeutic window: what is the optimal dose-per-fraction for high dose rate cervix cancer brachytherapy? Int J Radiat Oncol Biol Phys. 1995;31:1011–3.CrossRefPubMed Orton GC. Width of the therapeutic window: what is the optimal dose-per-fraction for high dose rate cervix cancer brachytherapy? Int J Radiat Oncol Biol Phys. 1995;31:1011–3.CrossRefPubMed
14.
Zurück zum Zitat Souhami L, Corns R, Duclos M, et al. Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. Gynecol Oncol. 2005;97:508–13.CrossRefPubMed Souhami L, Corns R, Duclos M, et al. Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. Gynecol Oncol. 2005;97:508–13.CrossRefPubMed
Metadaten
Titel
High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??
verfasst von
Saptarshi Ghosh
Pamidimukalabramhananda Rao
Publikationsdatum
17.12.2015
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-015-0812-8

Weitere Artikel der Sonderheft 1/2016

The Journal of Obstetrics and Gynecology of India 1/2016 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.